Deguelin reduced the expression of HIF-1α in lung cancer (H1299), human squamous cell carcinoma (UMSCC38), prostate cancer (PC3), gastric cancer (MKN-45), and breast cancer (MCF-7) cell lines, as well as in vascular endothelial cells. Here, HIF1A is linked to prostate cancer.